Engineered T cells that have been used to treat ulcerative colitis, rheumatoid arthritis and lupus show promising results.

Today, a new approach is giving patients and their physicians reason to hope. Moffitt Cancer Center has expanded its ...

A pioneering preclinical study has shown that CAR T cell therapy-a personalized form of immunotherapy used in cancer ...

With a five-year survival rate of less than 5%, glioblastoma is one of the most aggressive types of brain cancer.

A new international multicenter study published in the Journal of Cellular and Molecular Medicine provides important real-world evidence on the use of CD19-targeted chimeric antigen receptor (CAR) ...

Explore the breakthrough of new CAR-T cell therapy for glioblastoma, offering hope against one of the deadliest brain cancers.

In an interview with Targeted Oncology, Frederick L. Locke, MD, discussed how the elimination of the REMS program for CAR T-cell therapy came about and what effects he hopes this will have on patient ...

Kyverna Therapeutics has reported deep, sustained improvements in autoimmune disease patients who received a single dose of its CAR T-cell therapy KYV-101. The data come from the phase 2 part of a ...

T-cell therapy represents a groundbreaking advancement in cancer treatment, particularly for hematological malignancies. Despite its potential to offer curative outcomes, the field faces significant ...

With a five-year survival rate of less than 5%, glioblastoma is one of the most aggressive types of brain cancer.

Nick Jacobson won a settlement after sepsis nearly killed him in jail. Now he's using that money to help other inmates access ...